Archives of Neuroscience

Published by: Kowsar

Intracerebral Hemorrhage in a Patient with Multiple Sclerosis Receiving Interferon Beta-1α

Sareh Shahmohammadi 1 , Seyed Ehsan Mohammadianinejad 1 , Mohammad Ali Sahraian 1 and Abdorreza Naser Moghadasi 1 , *
Authors Information
1 MS Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran
Article information
  • Archives of Neuroscience: April 2017, 4 (2); e42758
  • Published Online: December 20, 2016
  • Article Type: Case Report
  • Received: October 8, 2016
  • Accepted: December 5, 2016
  • DOI: 10.5812/archneurosci.42758

To Cite: Shahmohammadi S, Mohammadianinejad S E, Sahraian M A, Moghadasi A N. Intracerebral Hemorrhage in a Patient with Multiple Sclerosis Receiving Interferon Beta-1α, Arch Neurosci. 2017 ; 4(2):e42758. doi: 10.5812/archneurosci.42758.

Abstract
Copyright © 2016, Tehran University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Footnote
References
  • 1. Ikram MA, Wieberdink RG, Koudstaal PJ. International epidemiology of intracerebral hemorrhage. Curr Atheroscler Rep. 2012; 14(4): 300-6[DOI][PubMed]
  • 2. Badjatia N, Rosand J. Intracerebral hemorrhage. Neurologist. 2005; 11(6): 311-24[PubMed]
  • 3. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci. 2007; 256 Suppl 1-8[DOI][PubMed]
  • 4. Marrie RA, Reider N, Cohen J, Stuve O, Sorensen PS, Cutter G, et al. A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. Mult Scler. 2015; 21(3): 282-93[DOI][PubMed]
  • 5. Sanford M, Lyseng-Williamson KA. Subcutaneous recombinant interferon-beta-1a (Rebif(R)): a review of its use in the treatment of relapsing multiple sclerosis. Drugs. 2011; 71(14): 1865-91[DOI][PubMed]
  • 6. Hartung HP, Haas J, Meergans M, Tracik F, Ortler S. [Interferon-beta1b in multiple sclerosis therapy: more than 20 years clinical experience]. Nervenarzt. 2013; 84(6): 679-704[DOI][PubMed]
  • 7. Galetta SL, Markowitz C. US FDA-approved disease-modifying treatments for multiple sclerosis: review of adverse effect profiles. CNS Drugs. 2005; 19(3): 239-52[PubMed]
  • 8. Deghima S, Chentli F. [Interferons and thyroid abnormalities: literature review]. Rev Med Liege. 2012; 67(3): 147-51[PubMed]
  • 9. Cavoli GL, Passantino R, Tortorici C, Bono L, Ferrantelli A, Rotolo U. Comment on thrombotic microangiopathy induced by interferon-beta therapy. Clin Nephrol. 2012; 78(6): 506-7[PubMed]
  • 10. Vosoughi R, Marriott JJ. Thrombotic microangiopathy in Interferon Beta treated multiple sclerosis patients: Review of literature and report of two new cases. Mult Scler Relat Disord. 2014; 3(3): 321-5[DOI][PubMed]
  • 11. Modrego PJ, Gazulla J. Arterial hypertension induced by interferon beta 1b in a patient with multiple sclerosis. Mult Scler. 2012; 18(11): 1655-6[DOI][PubMed]
  • 12. Rot U, Ledinek AH. Interferons beta have vasoconstrictive and procoagulant effects: a woman who developed livedo reticularis and Raynaud phenomenon in association with interferon beta treatment for multiple sclerosis. Clin Neurol Neurosurg. 2013; 115 Suppl 1-81[DOI][PubMed]
  • 13. Rodriguez-Vico JS, Mendoza A, Duarte J. [Livedo reticularis following subcutaneous injection of interferon beta-1b]. Rev Neurol. 2010; 51(1): 62[PubMed]
  • 14. Niederwieser G. Lethal capillary leak syndrome after a single administration of interferon beta-1b. Neurology. 2000; 54(7): 1545-6[PubMed]
  • 15. Gibbons E, Promislow S, Davies RA, Chandy G, Stewart DJ, Vladamir CD, et al. Reversible pulmonary arterial hypertension associated with interferon-beta treatment for multiple sclerosis. Can Respir J. 2015; 22(5): 263-5[PubMed]
  • 16. Gaetani L, Menduno PS, Cometa F, Di Gregorio M, Sarchielli P, Cagini C, et al. Retinopathy during interferon-beta treatment for multiple sclerosis: case report and review of the literature. J Neurol. 2016; 263(3): 422-7[DOI][PubMed]
  • 17. Al-Zahrani H, Gupta V, Minden MD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003; 44(3): 471-5[DOI][PubMed]
  • 18. Niederwieser G, Bonelli RM, Kammerhuber F, Reisecker F, Koltringer P. Intracerebral haemorrhage under interferon-beta therapy. Eur J Neurol. 2001; 8(4): 363-4[PubMed]
  • 19. Nishiofuku M, Tsujimoto T, Matsumura Y, Toyohara M, Yoshiji H, Yamao J, et al. Intracerebral hemorrhage in a patient receiving combination therapy of pegylated interferon alfa-2b and ribavirin for chronic hepatitis C. Internal Med. 2006; 45(7): 483-4[DOI]
  • 20. Ferencz S, Batey R. Intracerebral haemorrhage and hepatitis C treatment. J Viral Hepat. 2003; 10(5): 401-3[PubMed]
  • 21. Okuno H, Hirota T, Shiozaki Y, Inoue K, Hagihara M, Sugasawa K, et al. [Interferon-associated retinopathy]. Nihon Rinsho. 1994; 52(7): 1919-23[PubMed]
  • 22. Goto T, Ohshima S, Miura K, Shibuya T, Sato W, Dohmen T, et al. A chronic subdural hematoma in a patient receiving combination therapy with pegylated interferon alfa-2b and ribavirin for chronic hepatitis C. Inter Med. 2013; 52(18): 2057-60[DOI]
  • 23. Pakulski LA, DiMarco LM. Severe vaginal bleeding associated with recombinant interferon beta-1B. Ann Pharmacother. 1997; 31(1): 50-2[PubMed]
  • 24. Kuga K, Hasumura S, Nagamori S, Toda G, Kitahara K. Intraocular hemorrhage developing during interferon therapy. Internal Med. 1996; 35(1): 15-8[DOI]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments